Veronique S. Chachay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Veronique S. Chachay has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Jennifer H. Martin
Chair of Clinical Pharmacology School of Medicine and Public Health, University of Newcastle Newcastle Australia
4 shared publications - Jeff Scott Coombes
School of Human Movement and Nutrition Sciences, The University of Queensland, St Lucia, Queensland, Australia
3 shared publications - Carl M. J. Kirkpatrick
Centre for Medicine Use and Safety Monash University Parkville Victoria Australia
2 shared publications - Elizabeth Ellen Powell
Department of Gastroenterology and Hepatology, Princess Alexandra Hospital, Woolloongabba, Australia
2 shared publications - Emily R. Cox
Global Sport and Movement Collaborative, University of Newcastle, Callaghan, NSW, Australia
2 shared publications - Ingrid J. Hickman
Faculty of Medicine The University of Queensland Brisbane Queensland Australia
2 shared publications
Latest Publications
- Open Access
- 7 October 2024
- Published by BMJ in BMJ Open Sport & Exercise Medicine
- Vol. 10 (4) , e002046
Low-volume combined aerobic and resistance high-intensity interval training in type 2 diabetes: a randomised controlled trial
Objective: The objective of this study was to compare the effects of novel, time-efficient, low-volume combined aerobic and resistance high-intensity interval training (C-HIIT), and current exercise guidelines (210 min/week of combined moderate-intensity continuous training (C-MICT)), with waitlist control (CON) on glycaemic control in people with type 2 diabetes mellitus (T2D). Methods: Sixty-nine low-active people with T2D were randomised to 8 weeks of supervised C-HIIT (78 min/week), supervised C-MICT (210 min/week), or waitlist CON. Those in waitlist CON were re-randomised to supervised C-HIIT/C-MICT at week 8. Following 8 weeks of supervised training, participants completed 10 months of self-directed exercise. Outcomes were assessed at baseline, week 8 and month 12. Participants in waitlist CON were only included in the exercise groups for the month 12 analysis. Analyses were completed using intention-to-treat analysis of covariance (n=69; week 8) and linear mixed modelling (n=63; month 12). Results: Compared with CON, at week 8, HbA1c decreased in C-HIIT (adjusted mean difference: –0.7% (95% CI –1.3, –0.2%)) and C-MICT (–1.2% (–1.9, –0.6%)). There were also improvements in C-HIIT and C-MICT versus CON at week 8 for fat mass (–1.9 (–3.1, –0.6) and –1.5 (–2.6, –0.4) kg, respectively), lean mass (1.5 (0.8, 2.3) and 0.9 (0.1, 1.7) kg), and exercise capacity (124 (77, 171) and 49 (5, 93) s). At month 12, adherence was low, and most measures returned to baseline. Conclusions: Low-volume C-HIIT (78 min/week) and C-MICT (210 min/week) improved glycaemic control, body composition and exercise capacity similarly over 8 weeks in people with T2D. However, at month 12, improvements were not maintained following self-directed exercise. Regardless, these data suggest that supervised low-volume C-HIIT is a time-efficient and effective strategy for improving outcomes in T2D.
- 7 October 2024
- Published by BMJ in BMJ Open Sport & Exercise Medicine
- Vol. 10 (4) , e002046
Open AccessLow-volume combined aerobic and resistance high-intensity interval training in type 2 diabetes: a randomised controlled trial
Objective: The objective of this study was to compare the effects of novel, time-efficient, low-volume combined aerobic and resistance high-intensity interval training (C-HIIT), and current exercise guidelines (210 min/week of combined moderate-intensity continuous training (C-MICT)), with waitlist control (CON) on glycaemic control in people with type 2 diabetes mellitus (T2D). Methods: Sixty-nine low-active people with T2D were randomised to 8 weeks of supervised C-HIIT (78 min/week), supervised C-MICT (210 min/week), or waitlist CON. Those in waitlist CON were re-randomised to supervised C-HIIT/C-MICT at week 8. Following 8 weeks of supervised training, participants completed 10 months of self-directed exercise. Outcomes were assessed at baseline, week 8 and month 12. Participants in waitlist CON were only included in the exercise groups for the month 12 analysis. Analyses were completed using intention-to-treat analysis of covariance (n=69; week 8) and linear mixed modelling (n=63; month 12). Results: Compared with CON, at week 8, HbA1c decreased in C-HIIT (adjusted mean difference: –0.7% (95% CI –1.3, –0.2%)) and C-MICT (–1.2% (–1.9, –0.6%)). There were also improvements in C-HIIT and C-MICT versus CON at week 8 for fat mass (–1.9 (–3.1, –0.6) and –1.5 (–2.6, –0.4) kg, respectively), lean mass (1.5 (0.8, 2.3) and 0.9 (0.1, 1.7) kg), and exercise capacity (124 (77, 171) and 49 (5, 93) s). At month 12, adherence was low, and most measures returned to baseline. Conclusions: Low-volume C-HIIT (78 min/week) and C-MICT (210 min/week) improved glycaemic control, body composition and exercise capacity similarly over 8 weeks in people with T2D. However, at month 12, improvements were not maintained following self-directed exercise. Regardless, these data suggest that supervised low-volume C-HIIT is a time-efficient and effective strategy for improving outcomes in T2D.
- Open Access
- 15 March 2022
- Published by Wiley in Clinical Obesity
- Vol. 12 (3) , e12519
Effects of fitness and fatness on age‐related arterial stiffening in people with type 2 diabetes
Summary: People with type 2 diabetes (T2D) are at a greater risk of cardiovascular disease than the general population. Both non‐modifiable (age) and modifiable (low aerobic fitness, high body fatness) factors are separately predictive of cardiovascular risk, although they often occur concomitantly. This study aimed to examine the (1) association between age and arterial stiffness, a subclinical marker of cardiovascular risk; and (2) effects of body fatness and aerobic fitness on age‐related increases in arterial stiffness in people with T2D. Data from 64 individuals with T2D (age 59.8 ± 8.7 years, 40% female, HbA1c8.4 ± 1.6%) were included in this cross‐sectional analysis. Carotid‐femoral pulse wave velocity (cfPWV) was used to quantify arterial stiffness. Aerobic fitness (relative V̇O2peak) was determined via indirect calorimetry during maximal exercise testing. Central body fatness was determined using waist circumference. Data were analysed using hierarchical multiple regressions. After adjustment for sex and duration of T2D, each one standard deviation (SD) increase in age (8.68 years) was associated with a 0.63 m·s−1increase in cfPWV (β = 0.416,p = 0.001). Following adjustment for aerobic fitness and body fatness, the standardized β was unchanged (0.417). A one SD increase in waist circumference (13.9 cm) and relative V̇O2peak(5.3 ml·kg−1·min−1) were associated with a similar magnitude of difference in cfPWV (0.47 m·s−1and −0.44 m·s−1, respectively). Therefore, age is a significant correlate of increased arterial stiffness in T2D, with higher aerobic fitness attenuating, and higher body fatness exacerbating, this increase. Interventions aimed at improving cardiovascular outcomes in people with T2D should target both increased aerobic fitness and reduced body fatness.
- 15 March 2022
- Published by Wiley in Clinical Obesity
- Vol. 12 (3) , e12519
Open AccessEffects of fitness and fatness on age‐related arterial stiffening in people with type 2 diabetes
Summary: People with type 2 diabetes (T2D) are at a greater risk of cardiovascular disease than the general population. Both non‐modifiable (age) and modifiable (low aerobic fitness, high body fatness) factors are separately predictive of cardiovascular risk, although they often occur concomitantly. This study aimed to examine the (1) association between age and arterial stiffness, a subclinical marker of cardiovascular risk; and (2) effects of body fatness and aerobic fitness on age‐related increases in arterial stiffness in people with T2D. Data from 64 individuals with T2D (age 59.8 ± 8.7 years, 40% female, HbA1c8.4 ± 1.6%) were included in this cross‐sectional analysis. Carotid‐femoral pulse wave velocity (cfPWV) was used to quantify arterial stiffness. Aerobic fitness (relative V̇O2peak) was determined via indirect calorimetry during maximal exercise testing. Central body fatness was determined using waist circumference. Data were analysed using hierarchical multiple regressions. After adjustment for sex and duration of T2D, each one standard deviation (SD) increase in age (8.68 years) was associated with a 0.63 m·s−1increase in cfPWV (β = 0.416,p = 0.001). Following adjustment for aerobic fitness and body fatness, the standardized β was unchanged (0.417). A one SD increase in waist circumference (13.9 cm) and relative V̇O2peak(5.3 ml·kg−1·min−1) were associated with a similar magnitude of difference in cfPWV (0.47 m·s−1and −0.44 m·s−1, respectively). Therefore, age is a significant correlate of increased arterial stiffness in T2D, with higher aerobic fitness attenuating, and higher body fatness exacerbating, this increase. Interventions aimed at improving cardiovascular outcomes in people with T2D should target both increased aerobic fitness and reduced body fatness.
- Open Access
“An Important Part of Who I am”: The Predictors of Dietary Adherence among Weight-Loss, Vegetarian, Vegan, Paleo, and Gluten-Free Dietary Groups
Weight-loss diets are notorious for their low adherence, which is a barrier to efforts to reduce population rates of overweight and obesity. However, there is some evidence that adherence is better among people on other kinds of diets, such as vegan and gluten free. This study aimed to explore the predictors of dietary adherence across five restrictive dietary patterns (vegan, vegetarian, paleo, gluten free, and weight loss). This study used both qualitative and quantitative methods among 292 adult community members who were following a restrictive dietary pattern. Personality, mental health, and motivational predictors of adherence were examined. Substantial differences in adherence were found between dietary groups, with vegans and vegetarians being particularly high in adherence and gluten-free and weight-loss dieters being comparably low. Four consistent predictors of adherence across different dietary patterns were supported in both the quantitative and qualitative analyses. Self-efficacy and social identification with one’s dietary group positively predicted adherence. Conversely, being motivated in one’s dietary choices by mood or by weight control negatively predicted adherence. These findings speak to the importance of social and motivational factors in determining adherence. The results also illustrate the utility of looking beyond weight-loss dieters and virtuous individual traits for insights into how adherence may be improved.
Open Access“An Important Part of Who I am”: The Predictors of Dietary Adherence among Weight-Loss, Vegetarian, Vegan, Paleo, and Gluten-Free Dietary Groups
Weight-loss diets are notorious for their low adherence, which is a barrier to efforts to reduce population rates of overweight and obesity. However, there is some evidence that adherence is better among people on other kinds of diets, such as vegan and gluten free. This study aimed to explore the predictors of dietary adherence across five restrictive dietary patterns (vegan, vegetarian, paleo, gluten free, and weight loss). This study used both qualitative and quantitative methods among 292 adult community members who were following a restrictive dietary pattern. Personality, mental health, and motivational predictors of adherence were examined. Substantial differences in adherence were found between dietary groups, with vegans and vegetarians being particularly high in adherence and gluten-free and weight-loss dieters being comparably low. Four consistent predictors of adherence across different dietary patterns were supported in both the quantitative and qualitative analyses. Self-efficacy and social identification with one’s dietary group positively predicted adherence. Conversely, being motivated in one’s dietary choices by mood or by weight control negatively predicted adherence. These findings speak to the importance of social and motivational factors in determining adherence. The results also illustrate the utility of looking beyond weight-loss dieters and virtuous individual traits for insights into how adherence may be improved.
- 6 August 2017
- Published by Wiley in Internal Medicine Journal
- Vol. 47 (8) , 952-955
Optimising care of patients with chronic disease: patient‐oriented education may improve disease knowledge and self‐management
Many patients with chronic disease do not possess the knowledge and skills required to access and interpret appropriate health information. A pilot study in people with liver cirrhosis (n = 50) identified that only 54% of patients could recall being given written information by a clinician and 64% had self‐sought information, most commonly using the Internet. Many patients reported difficulties understanding the material and the majority wanted more accessible information. A pilot chronic disease educational booklet was well received by the study participants with 85% reporting it was helpful and 78% using it in between clinic appointments.
- 6 August 2017
- Published by Wiley in Internal Medicine Journal
- Vol. 47 (8) , 952-955
Optimising care of patients with chronic disease: patient‐oriented education may improve disease knowledge and self‐management
Many patients with chronic disease do not possess the knowledge and skills required to access and interpret appropriate health information. A pilot study in people with liver cirrhosis (n = 50) identified that only 54% of patients could recall being given written information by a clinician and 64% had self‐sought information, most commonly using the Internet. Many patients reported difficulties understanding the material and the majority wanted more accessible information. A pilot chronic disease educational booklet was well received by the study participants with 85% reporting it was helpful and 78% using it in between clinic appointments.
- 31 January 2017
- Published by Springer Nature
- p. 1651-1665
Nutrition in Aging, An Exploration of a Close Relationship
- 31 January 2017
- Published by Springer Nature
- p. 1651-1665
Nutrition in Aging, An Exploration of a Close Relationship
- Open Access
- 13 September 2016
- Published by Springer Nature in BMC Gastroenterology
- Vol. 16 (1) , 114
Prevalence of medication discrepancies in patients with cirrhosis: a pilot study
Cirrhosis patients are prescribed multiple medications for their liver disease and comorbidities. Discrepancies between medicines consumed by patients and those documented in the medical record may contribute to patient harm and impair disease management. The aim of the present study was to assess the magnitude and types of discrepancies among patient-reported and medical record-documented medications in patients with cirrhosis, and examine factors associated with such discrepancies. Fifty patients who attended a hospital hepatology outpatient clinic were interviewed using a questionnaire composed of mixed short-response and multiple-choice questions. Patients’ reported medication use was compared with documentation in the hospital medical records and pharmacy database. Medication adherence was assessed using the 8-question ©Morisky Medication Adherence Scale (MMAS-8). The multivariate logistic regression model was constructed using clinically relevant and/or statistically significant variables as determined by univariate analysis. All p-values were 2-sided (α = 0.05). Twenty-seven patients (54.0 %) had ≥1 discrepancy between reported and documented medicines. Patients with ≥1 discrepancy were older (p = 0.04) and multivariate analysis identified taking ≥5 conventional medicines or having a ‘low’ or ‘medium’ adherence ranking as independent predictors of discrepancy (adjusted OR 11.0 (95 % CI 1.8–67.4), 20.7 (95 % CI 1.3–337.7) and 49.0 (95 % CI 3.3–718.5) respectively). Concordance was highest for liver disease medicines (71.9 %) and lowest for complementary and alternative medicines (14.5 %) and respiratory medicines (0 %). There is significant discrepancy between sources of patient medication information within the hepatology clinic. Medication reconciliation and medicines-management intervention may address the complex relationship between medication discrepancies, number of medications and patient adherence identified in this study.
- 13 September 2016
- Published by Springer Nature in BMC Gastroenterology
- Vol. 16 (1) , 114
Open AccessPrevalence of medication discrepancies in patients with cirrhosis: a pilot study
Cirrhosis patients are prescribed multiple medications for their liver disease and comorbidities. Discrepancies between medicines consumed by patients and those documented in the medical record may contribute to patient harm and impair disease management. The aim of the present study was to assess the magnitude and types of discrepancies among patient-reported and medical record-documented medications in patients with cirrhosis, and examine factors associated with such discrepancies. Fifty patients who attended a hospital hepatology outpatient clinic were interviewed using a questionnaire composed of mixed short-response and multiple-choice questions. Patients’ reported medication use was compared with documentation in the hospital medical records and pharmacy database. Medication adherence was assessed using the 8-question ©Morisky Medication Adherence Scale (MMAS-8). The multivariate logistic regression model was constructed using clinically relevant and/or statistically significant variables as determined by univariate analysis. All p-values were 2-sided (α = 0.05). Twenty-seven patients (54.0 %) had ≥1 discrepancy between reported and documented medicines. Patients with ≥1 discrepancy were older (p = 0.04) and multivariate analysis identified taking ≥5 conventional medicines or having a ‘low’ or ‘medium’ adherence ranking as independent predictors of discrepancy (adjusted OR 11.0 (95 % CI 1.8–67.4), 20.7 (95 % CI 1.3–337.7) and 49.0 (95 % CI 3.3–718.5) respectively). Concordance was highest for liver disease medicines (71.9 %) and lowest for complementary and alternative medicines (14.5 %) and respiratory medicines (0 %). There is significant discrepancy between sources of patient medication information within the hepatology clinic. Medication reconciliation and medicines-management intervention may address the complex relationship between medication discrepancies, number of medications and patient adherence identified in this study.
- 12 May 2016
- Published by Springer Nature
- p. 1-15
Nutrition in Aging: An Exploration of a Close Relationship
- 12 May 2016
- Published by Springer Nature
- p. 1-15
Nutrition in Aging: An Exploration of a Close Relationship
- 1 December 2014
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 12 (12) , 2092-2103.e6
Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease
- 1 December 2014
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 12 (12) , 2092-2103.e6
Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease
- 1 September 2014
- Published by University of Queensland Library
Clinical investigation of resveratrol supplementation in the management of cardiometabolic dysregulation in non-alcoholic fatty liver disease
The University of Queensland's institutional repository, UQ eSpace, aims to create global visibility and accessibility of UQ’s scholarly research.
- 1 September 2014
- Published by University of Queensland Library
Clinical investigation of resveratrol supplementation in the management of cardiometabolic dysregulation in non-alcoholic fatty liver disease
The University of Queensland's institutional repository, UQ eSpace, aims to create global visibility and accessibility of UQ’s scholarly research.
- 9 June 2011
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 72 (1) , 27-38
Resveratrol – pills to replace a healthy diet?
Nutrapharmacology, or the use of bioactive food compounds at pharmacological doses is emerging as a therapeutic approach to target the complex metabolic dysregulations in ageing and obesity‐related chronic disease. Resveratrol, a polyphenol found in the skin of grapes, and other edible plants and related food products, has received extensive attention through the link with the French paradox, and later with its chemopreventive activity demonstrated in vitro and in animal cancer models. A plethora of laboratory investigations has provided evidence for the multi‐faceted properties of resveratrol and suggests that resveratrol may target ageing and obesity‐related chronic disease by regulating inflammation and oxidative stress. A number of obstacles stand in the path to clinical usage however, not least the lack of clinical evidence to date, and the myriad of doses and formulations available. Further, data on the effects of resveratrol consumption in a capsule vs. food form is conflicting, and there are uncertain effects of long term dosing. The review will summarize the human pharmacokinetic and pharmacodynamic published data, and the topics for research if resveratrol is to become a multi‐target therapeutic agent addressing chronic disease.
- 9 June 2011
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 72 (1) , 27-38
Resveratrol – pills to replace a healthy diet?
Nutrapharmacology, or the use of bioactive food compounds at pharmacological doses is emerging as a therapeutic approach to target the complex metabolic dysregulations in ageing and obesity‐related chronic disease. Resveratrol, a polyphenol found in the skin of grapes, and other edible plants and related food products, has received extensive attention through the link with the French paradox, and later with its chemopreventive activity demonstrated in vitro and in animal cancer models. A plethora of laboratory investigations has provided evidence for the multi‐faceted properties of resveratrol and suggests that resveratrol may target ageing and obesity‐related chronic disease by regulating inflammation and oxidative stress. A number of obstacles stand in the path to clinical usage however, not least the lack of clinical evidence to date, and the myriad of doses and formulations available. Further, data on the effects of resveratrol consumption in a capsule vs. food form is conflicting, and there are uncertain effects of long term dosing. The review will summarize the human pharmacokinetic and pharmacodynamic published data, and the topics for research if resveratrol is to become a multi‐target therapeutic agent addressing chronic disease.